A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2

A. C. Ogilvie; J. W. Baars; A. J M Eerenberg; C. E. Hack; H. M. Pinedo; L. G. Thijs; J. Wagstaff

A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2

A. C. Ogilvie, J. W. Baars, A. J M Eerenberg, C. E. Hack, H. M. Pinedo, L. G. Thijs, J. Wagstaff

Research output: Contribution to journal › Article › peer-review

Abstract

In a pilot study six patients received 4 days' treatment with interleukin 2 (IL-2) [cumulative dose (CD) 264 ± 26 × 10⁶ IU m^-2] and Cl esterase inhibitor (Cl-INH) (loading dose 2,000 U, followed by 500-1,000 U twice daily). Toxicity was compared with that in patients given 4 days' treatment with standard (CD 66 ± 12 × 10⁶ IU m^-2) or escalating-dose (CD 99 ± 8 × 10⁶ IU m^-2) IL-2. IL-2-induced hypotension was equivalent and complement activation was less after IL-2 + Cl-INH (C3a = 10.5 ± 3.2 nmol 1^-1) than following standard (14.1 ± 8.4 nmol 1^-1) or escalating-dose (18.3 ± 2.9 nmnol l^-1) IL-2. This study demonstrates that C1-INH administration during IL-2 treatment is safe and warrants further study to evaluate its ability to ameliorate IL-2-induced toxicity.

Original language	English (US)
Pages (from-to)	596-598
Number of pages	3
Journal	British Journal of Cancer
Volume	69
Issue number	3
State	Published - Mar 1994
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{fd3f78ebaf7b40daba5a36d563a1cb06,

title = "A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2",

abstract = "In a pilot study six patients received 4 days' treatment with interleukin 2 (IL-2) [cumulative dose (CD) 264 ± 26 × 106 IU m-2] and Cl esterase inhibitor (Cl-INH) (loading dose 2,000 U, followed by 500-1,000 U twice daily). Toxicity was compared with that in patients given 4 days' treatment with standard (CD 66 ± 12 × 106 IU m-2) or escalating-dose (CD 99 ± 8 × 106 IU m-2) IL-2. IL-2-induced hypotension was equivalent and complement activation was less after IL-2 + Cl-INH (C3a = 10.5 ± 3.2 nmol 1-1) than following standard (14.1 ± 8.4 nmol 1-1) or escalating-dose (18.3 ± 2.9 nmnol l-1) IL-2. This study demonstrates that C1-INH administration during IL-2 treatment is safe and warrants further study to evaluate its ability to ameliorate IL-2-induced toxicity.",

author = "Ogilvie, {A. C.} and Baars, {J. W.} and Eerenberg, {A. J M} and Hack, {C. E.} and Pinedo, {H. M.} and Thijs, {L. G.} and J. Wagstaff",

year = "1994",

month = mar,

language = "English (US)",

volume = "69",

pages = "596--598",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2

AU - Ogilvie, A. C.

AU - Baars, J. W.

AU - Eerenberg, A. J M

AU - Hack, C. E.

AU - Pinedo, H. M.

AU - Thijs, L. G.

AU - Wagstaff, J.

PY - 1994/3

Y1 - 1994/3

N2 - In a pilot study six patients received 4 days' treatment with interleukin 2 (IL-2) [cumulative dose (CD) 264 ± 26 × 106 IU m-2] and Cl esterase inhibitor (Cl-INH) (loading dose 2,000 U, followed by 500-1,000 U twice daily). Toxicity was compared with that in patients given 4 days' treatment with standard (CD 66 ± 12 × 106 IU m-2) or escalating-dose (CD 99 ± 8 × 106 IU m-2) IL-2. IL-2-induced hypotension was equivalent and complement activation was less after IL-2 + Cl-INH (C3a = 10.5 ± 3.2 nmol 1-1) than following standard (14.1 ± 8.4 nmol 1-1) or escalating-dose (18.3 ± 2.9 nmnol l-1) IL-2. This study demonstrates that C1-INH administration during IL-2 treatment is safe and warrants further study to evaluate its ability to ameliorate IL-2-induced toxicity.

AB - In a pilot study six patients received 4 days' treatment with interleukin 2 (IL-2) [cumulative dose (CD) 264 ± 26 × 106 IU m-2] and Cl esterase inhibitor (Cl-INH) (loading dose 2,000 U, followed by 500-1,000 U twice daily). Toxicity was compared with that in patients given 4 days' treatment with standard (CD 66 ± 12 × 106 IU m-2) or escalating-dose (CD 99 ± 8 × 106 IU m-2) IL-2. IL-2-induced hypotension was equivalent and complement activation was less after IL-2 + Cl-INH (C3a = 10.5 ± 3.2 nmol 1-1) than following standard (14.1 ± 8.4 nmol 1-1) or escalating-dose (18.3 ± 2.9 nmnol l-1) IL-2. This study demonstrates that C1-INH administration during IL-2 treatment is safe and warrants further study to evaluate its ability to ameliorate IL-2-induced toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0028354749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028354749&partnerID=8YFLogxK

M3 - Article

C2 - 8123494

AN - SCOPUS:0028354749

SN - 0007-0920

VL - 69

SP - 596

EP - 598

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 3

ER -

A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this